Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of BridgeBio Pharma's BBP-631?
BBP-631 is a gene therapy commercialized by BridgeBio Pharma, with a leading Phase II program in Congenital Adrenal Hyperplasia (Adrenogenital...